新闻

Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?

NASDAQ

Key PointsNovo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly.

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论,并结合市场和 OSINT 背景分析。